Literature DB >> 29594584

Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT.

V Dell'Acqua1, J Kobiela2, F Kraja3, M C Leonardi4, A Surgo1, M A Zerella1,5, S Arculeo1,5, C Fodor1, R Ricotti1, M G Zampino6, S Ravenda6, G Spinoglio7, R Biffi8, A Bazani9, R Luraschi9, S Vigorito9, P Spychalski2, R Orecchia10, R Glynne-Jones11, B A Jereczek-Fossa1,5.   

Abstract

Intensity-modulated radiotherapy (IMRT) is considered the preferred option in squamous cell canal cancer (SCAC), delivering high doses to tumor volumes while minimizing dose to surrounding normal tissues. IMRT has steep dose gradients, but the technique is more demanding as deep understanding of target structures is required. To evaluate genital marginal failure in a cohort of patients with non-metastatic SCAC treated either with IMRT or 3DCRT and concurrent chemotherapy, 117 patients with SCAC were evaluated: 64 and 53 patients were treated with IMRT and 3DCRT techniques, respectively. All patients underwent clinical and radiological examination during their follow-up. Tumor response was evaluated with response evaluation criteria in solid tumors v1.1 guideline on regular basis. All patients' data were analyzed, and patients with marginal failure were identified. Concomitant chemotherapy was administered in 97 and 77.4% of patients in the IMRT and 3DCRT groups, respectively. In the IMRT group, the median follow-up was 25 months (range 6-78). Progressive disease was registered in 15.6% of patients; infield recurrence, distant recurrence and both infield recurrence and distant recurrence were identified in 5, 4 and 1 patient, respectively. Two out of 64 patients (3.1%) had marginal failures, localized at vagina/recto-vaginal septum and left perineal region. In the 3DCRT group, the median follow-up was 71.3 months (range 6-194 months). Two out of 53 patients (3.8%) had marginal failures, localized at recto-vaginal septum and perigenital structures. The rate of marginal failures was comparable in IMRT and 3DCRT groups (χ2 test p = 0.85). In this series, the use of IMRT for the treatment of SCAC did not increase the rate of marginal failures offering improved dose conformity to the target. Dose constraints should be applied with caution-particularly in females with involvement of the vagina or the vaginal septum.

Entities:  

Keywords:  Anal cancer; Anal carcinoma; Genital marginal failures; IMRT; Radiotherapy; Squamous cell anal cancer

Mesh:

Year:  2018        PMID: 29594584     DOI: 10.1007/s12032-018-1118-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

1.  Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.

Authors:  Jean L Wright; Sujata M Patil; Larissa K F Temple; Bruce D Minsky; Leonard B Saltz; Karyn A Goodman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-29       Impact factor: 7.038

2.  NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.

Authors:  Akila N Viswanathan; Jennifer Moughan; Brigitte E Miller; Ying Xiao; Anuja Jhingran; Lorraine Portelance; Walter R Bosch; Ursula A Matulonis; Neil S Horowitz; Robert S Mannel; Luis Souhami; Beth A Erickson; Kathryn A Winter; William Small; David K Gaffney
Journal:  Cancer       Date:  2015-04-06       Impact factor: 6.860

3.  Anal cancer - a review.

Authors:  Sajad Ahmad Salati; Azzam Al Kadi
Journal:  Int J Health Sci (Qassim)       Date:  2012-06

4.  Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.

Authors:  R Glynne-Jones; P J Nilsson; C Aschele; V Goh; D Peiffert; A Cervantes; D Arnold
Journal:  Eur J Surg Oncol       Date:  2014-10       Impact factor: 4.424

5.  Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.

Authors:  H Bartelink; F Roelofsen; F Eschwege; P Rougier; J F Bosset; D G Gonzalez; D Peiffert; M van Glabbeke; M Pierart
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

6.  Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome.

Authors:  Sushil Beriwal; Dwight E Heron; Hayeon Kim; Gwendolyn King; Jeffrey Shogan; Sanjeev Bahri; Kristina Gerszten; Joe Lee; Joseph Kelley; Robert P Edwards
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-25       Impact factor: 7.038

7.  Proposed genitalia contouring guidelines in anal cancer intensity-modulated radiotherapy.

Authors:  C Brooks; V N Hansen; A Riddell; V A Harris; D M Tait
Journal:  Br J Radiol       Date:  2015-05-08       Impact factor: 3.039

8.  Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314.

Authors:  B Sischy; R L Doggett; J M Krall; D G Taylor; W T Sause; J A Lipsett; H G Seydel
Journal:  J Natl Cancer Inst       Date:  1989-06-07       Impact factor: 13.506

9.  Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.

Authors:  Pierfrancesco Franco; Francesca Arcadipane; Riccardo Ragona; Massimiliano Mistrangelo; Paola Cassoni; Nadia Rondi; Mario Morino; Patrizia Racca; Umberto Ricardi
Journal:  Anticancer Res       Date:  2016-04       Impact factor: 2.480

10.  Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer.

Authors:  Sabine Mai; Grit Welzel; Martine Ottstadt; Frank Lohr; Sebastin Severa; Elena-Sophie Prigge; Nicolas Wentzensen; Marcus J Trunk; Frederik Wenz; Magnus von Knebel-Doeberitz; Miriam Reuschenbach
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-08-07       Impact factor: 7.038

View more
  5 in total

1.  Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy.

Authors:  Veronica Dell'Acqua; Alessia Surgo; Simona Arculeo; Maria Alessia Zerella; Vincenzo Bagnardi; Samuele Frassoni; Maria Giulia Zampino; Paola Simona Ravenda; Maria Saveria Rotundo; Fatjona Kraja; Jarek Kobiela; Piotr Spychalski; Cristiana Fodor; Marianna Alessandra Gerardi; Federica Cattani; Alessia Bazani; Wanda Petz; Robert Glynne-Jones; Roberto Orecchia; Maria Cristina Leonardi; Barbara Alicja Jereczek-Fossa
Journal:  Int J Colorectal Dis       Date:  2020-02-08       Impact factor: 2.571

2.  Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.

Authors:  Lisa A Kachnic; Kathryn A Winter; Robert J Myerson; Michael D Goodyear; Andre A Abitbol; Oscar E Streeter; Mark E Augspurger; Tracey E Schefter; Alan W Katz; Barbara J Fisher; Lauren E Henke; Samir Narayan; Christopher H Crane
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-14       Impact factor: 8.013

3.  The impact of contour variation on tumour control probability in anal cancer.

Authors:  Michael P Jones; Jarad Martin; Kerwyn Foo; Patrick Estoesta; Lois Holloway; Michael Jameson
Journal:  Radiat Oncol       Date:  2018-05-18       Impact factor: 3.481

4.  Patterns of recurrence in anal cancer: a detailed analysis.

Authors:  Martin P Nilsson; Erik D Nilsson; Anders Johnsson; Otilia Leon; Adalsteinn Gunnlaugsson; Jonas Scherman
Journal:  Radiat Oncol       Date:  2020-05-27       Impact factor: 3.481

5.  Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma.

Authors:  Rebecca Shakir; Richard Adams; Rachel Cooper; Amy Downing; Ian Geh; Duncan Gilbert; Clare Jacobs; Christopher Jones; Cressida Lorimer; Wanangwa C Namelo; David Sebag-Montefiore; Paul Shaw; Rebecca Muirhead
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-10-17       Impact factor: 7.038

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.